DailyIQ
Last updated 8 minutes ago

RVTY·Revvity, Inc.

$.
+. (+.%)
After Hours
High
$115.51
Open
$114.98
Market Cap
12.77B
52W High
$118.30
Low
$113.73
P. Close
$114.66
P/E
53.75
52W Low
$81.22
Fwd P/E
19.46
DailyIQ Est.
-
Technical Score (1D)
86
BUY
News Sentiment
79
BULLISH
Revvity’s Q2 2026 results beat expectations with $51.82 million net income and $729.69 million in sales, prompting the company to lift its full‑year 2026 revenue guidance to $2.83‑$2.86 billion, a move that signals a bullish outlook and warrants attention to the next quarterly guidance for further upside. Management cited stronger pharma and biotech spending, robust diagnostics growth—especially in reproductive health—and progress on exiting its China immunodiagnostics business as the drivers behind the revised outlook, implying a higher‑margin focus that traders should monitor for the pace of the China divestiture and its impact on the revenue mix. The China exit marks a strategic shift toward higher‑margin diagnostics and cloud‑security services, which could improve operating leverage over the next 10 trading days, so watch for any regulatory or execution delays that might affect the transition. Analysts have responded to the earnings beat by raising price targets, with Bernstein lifting its target to $120, Evercore ISI to $126, and Stifel to $110, while maintaining outperform or market‑perform ratings, reinforcing the bullish case and suggesting that investors will keep an eye on any subsequent target revisions or rating changes. The consensus of multiple upgrades indicates growing confidence in Revvity’s subscription‑based cloud platform and diagnostics pipeline, reinforcing the bullish case for the next few weeks and warranting close observation of upcoming earnings releases for guidance updates. The company also highlighted AI‑driven demand as a key growth lever, indicating that continued investment in AI capabilities could further accelerate revenue growth, so traders should watch progress on AI integration and new product launches. Regulatory developments in the life‑sciences and cloud‑security sectors could affect Revvity’s growth trajectory, so monitoring any policy announcements is prudent. In addition, the firm’s focus on expanding enterprise contracts and cost‑control initiatives may enhance profitability, so keeping an eye on margin trends in the next earnings cycle is advisable. Overall, the combination of a strong earnings beat, higher guidance, analyst upgrades, and a strategic shift away from China positions Revvity favorably for the next 1–10 trading days, but traders should watch the China exit execution, AI progress, and upcoming guidance for any new catalysts.
Earnings Summary
Revvity, Inc. (RVTY) is a provider of health‑science solutions headquartered in Waltham, Massachusetts, offering instruments, reagents, software, and services that support genetic testing, diagnostics, and drug discovery across pharmaceutical, research, and healthcare markets. Operating in the diagnostics and research sector, the company has a long history dating back to 1937 and recently transitioned from its former identity as PerkinElmer. In its most recent earnings cycle, Revvity reported Q1 2026 EPS of $1.06 versus an estimate of $1.23 and revenue of $711.12 million versus $735.97 million, a slight decline from Q4 2025 EPS of $1.70 and revenue of $772.06 million; however, the Q2 2026 quarter delivered a stronger EPS of $1.41 versus an estimate of $1.25 and revenue of $729.69 million versus $720.28 million, indicating a rebound in profitability and sales momentum. Across the last four quarters, Revvity has consistently beat earnings estimates, with EPS exceeding forecasts in Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026, and Q2 2026, while revenue growth has remained positive, rising from $729.58 million in Q4 2024 to $772.06 million in Q4 2025 and then to $729.69 million in Q2 2026, reflecting a steady upward trajectory. The company’s historical streak shows a pattern of robust earnings beats and modest revenue increases, underscoring disciplined cost management and a growing diagnostics pipeline. Recent news highlights Revvity’s Q2 2026 earnings beat, a lift of its full‑year 2026 revenue guidance to $2.83–$2.86 billion, and a strategic exit from its China immunodiagnostics business, which is expected to shift the revenue mix toward higher‑margin U.S. and European markets; analysts have responded with price‑target upgrades and maintained outperform ratings. Investors should watch for the execution of the China divestiture, the pace of AI‑driven diagnostics integration, and the company’s forthcoming guidance on FY 2026 margins, as these factors will shape the next quarter’s performance and valuation dynamics.

EPS

EstBeatMiss
$0.96$1.17$1.38$1.59$1.80Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.29 - -
Q2'26$1.25$1.41+13.1%
Q1'26$1.23$1.06-13.8%
Q4'25$1.58$1.70+7.5%
Q3'25$1.14$1.18+3.6%
Q2'25$1.14$1.18+3.4%

Revenue

EstBeatMiss
$687M$713M$738M$763M$788MQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$711M - -
Q2'26$723M$730M+0.9%
Q1'26$736M$711M-3.4%
Q4'25$777M$772M-0.6%
Q3'25 - $699M -
Q2'25 - $720M -

Market Data

RVTY Stock Snapshot

RVTY is currently trading at $114.66, giving Revvity, Inc. a market cap of 12.77B and a P/E ratio of 53.8. Today's range spans $113.73–$115.51, with shares opening at $114.98 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 79/100.

Over the past year RVTY has traded between $81.22 and $118.30 - the current price is +41.2% off the 52-week low and -3.1% from the high.

In the Healthcare peer group, Revvity, Inc. (RVTY) stands out for a BUY signal backed by aligned sentiment - score 86/100, sentiment bullish at 79/100, price $114.66 (near 52-week highs). (P/E: 53.8) With 12.77B in market cap, this is large enough to feature on institutional watch lists but small enough to re-rate meaningfully on a positive earnings surprise. The 52-week span of $81.22–$118.30 shows the stock has already proven it can make significant moves.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (79/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $114.66 (near 52-week highs), RVTY's position within the $81.22–$118.30 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.

Last updated: August 8, 2026

Company Insights: Revvity, Inc. (RVTY)

Revvity, Inc., formerly PerkinElmer, operates as a key provider of health science solutions, focusing on technologies and services essential for research, diagnostics, and drug discovery. The company's core offerings encompass instruments, reagents, and software designed to facilitate advanced genetic testing and analysis. These tools are critical for applications ranging from the early detection of genetic disorders to infectious disease testing and comprehensive genomic workflows. Revvity serves a broad customer base, including pharmaceutical giants, academic research institutions, and healthcare providers, underscoring its integral role in the life sciences ecosystem.

The company's strategic emphasis on innovation is evident in its recent introduction of new platforms at SLAS2026, aimed at accelerating drug discovery. Products like the Opera Phenix OptIQ high-content screening system and the EnVision Nexus One multimode plate reader are designed to enhance research efficiency. These advanced systems, alongside the AssayMate workstation, represent Revvity's commitment to providing cutting-edge solutions for complex biological challenges. Such technological advancements are crucial for maintaining a competitive edge in the rapidly evolving diagnostics and research markets.

Financial performance indicates a positive trajectory in earnings per share (EPS) and revenue over the last four reported quarters. Revvity has consistently surpassed EPS estimates, reflecting effective operational execution and demand for its solutions. While revenue shows an upward trend, investors are advised to monitor the impact of new product launches on future earnings growth. Concurrently, potential headwinds such as valuation concerns and market dynamics in specific regions, like China diagnostics, warrant careful consideration in assessing the company's overall outlook.

Diagnostics & Research

Provides essential instruments, reagents, and software for genetic testing and analysis.

Supports critical applications including newborn screening, oncology research, and immunodiagnostics.

Serves a diverse customer base of pharmaceutical companies, research institutions, and healthcare providers.

Drug Discovery Acceleration

Launched new platforms like Opera Phenix OptIQ and EnVision Nexus One at SLAS2026.

These systems aim to enhance high-content screening and multimode plate reading capabilities.

Focuses on accelerating complex drug discovery workflows for its clients.

Financial Performance

Demonstrated consistent EPS growth and beat estimates in all recent quarters.

Revenue trends upwards, supported by demand for its health science solutions.

New product impact and regional market dynamics will influence future earnings.

Market Position

Operates within the Diagnostics & Research industry in the United States.

Formerly known as PerkinElmer, with a history dating back to 1937.

Faces competition and potential market weakness in specific segments like China diagnostics.

Positioning RVTY

Revvity's consistent EPS growth and new product introductions present opportunities for investors. Exposure may be increased following successful integration and demonstrated revenue acceleration from new platforms. Conversely, significant weakness in key diagnostic markets or persistent valuation concerns could warrant a reduction in position size.

Risk Factors

Revvity's risk profile is tied to its innovation pipeline, regulatory environment, and global market dynamics. Investors should monitor the successful integration of new technologies and the company's ability to navigate specific regional market challenges.

  • China Diagnostics

    Weakness in the China diagnostics market poses a direct threat to Revvity's revenue streams. A slowdown in this key region, driven by economic factors or increased local competition, could negatively impact sales. This risk would materialize if reported sales from China continue to decline or fail to meet growth expectations.

  • Product Innovation

    Revvity's growth relies heavily on the successful development and adoption of new platforms and technologies. Failure to innovate or commercialize new products effectively could lead to market share erosion. This risk becomes critical if competitors launch superior solutions or if new Revvity products underperform commercially.

  • Valuation Concerns

    The company's current valuation may present a risk if future growth does not meet investor expectations. High multiples can lead to significant stock price declines if earnings or revenue growth falters. This concern would be amplified if the company misses earnings targets or revises its forward guidance downwards.

  • Regulatory Scrutiny

    As a provider of health science solutions, Revvity is subject to evolving regulatory standards in its key markets. Changes in regulations concerning diagnostics or drug discovery could increase compliance costs or impact product approvals. This risk would materialize if new regulations are introduced that hinder Revvity's operations or product lifecycles.

Analyst Price Targets for RVTY

The current spread of analyst price targets and ratings for Revvity, Inc. (RVTY).

Consensus Target
$119.56
High Target
$140.0
Low Target
$105.0
Buy / Hold / Sell
15 / 10 / 1

Reflects the most recently tracked analyst ratings for RVTY and may lag real-time updates. Not a recommendation to buy or sell.

Key Metrics for RVTY

Revvity's performance hinges on innovation in diagnostics and research tools. Investors should monitor key operational and financial metrics to gauge its growth trajectory and market position.

Revenue Growth: Measures the increase in Revvity's total sales quarter-over-quarter and year-over-year. Accelerating revenue growth indicates strong demand for its health science solutions; slowing growth could signal market saturation or competitive pressures. This is crucial for RVTY as it directly impacts profitability and its ability to fund R&D for new technologies.

EPS Growth: Tracks the increase in Revvity's earnings per share. Consistent EPS growth, especially when beating estimates, suggests effective cost management and operational efficiency; declining EPS is a red flag. For RVTY, this metric reflects the company's ability to translate revenue into shareholder value.

New Product Adoption: Assesses the market uptake and revenue contribution from recently launched instruments and reagents, such as the Opera Phenix OptIQ and EnVision Nexus One. Strong adoption validates Revvity's innovation pipeline; weak adoption suggests R&D missteps or poor market fit. This is vital for RVTY's long-term competitive advantage and future growth.

Genetic Testing Volume: Monitors the number of genetic tests and analyses performed using Revvity's platforms and reagents. Higher volumes indicate increased utilization in diagnostics and research; a decline may point to shifts in healthcare trends or competition. This metric is fundamental to RVTY's core business and its impact on early disease detection and genomic workflows.

R&D Investment: Examines the level of capital Revvity allocates to research and development. Increased R&D spending signals a commitment to innovation and future growth; significant cuts could jeopardize its competitive edge. For RVTY, sustained R&D is essential to maintain leadership in the rapidly evolving health sciences sector.

RVTY Recent Earnings History

  • Q4 2025

    EPS: $1.7 actual vs $1.58 estimate (beat) · Revenue: $772M actual vs $777M estimate

  • Q3 2025

    EPS: $1.18 actual vs $1.14 estimate (beat) · Revenue: $699M actual

  • Q2 2025

    EPS: $1.18 actual vs $1.14 estimate (beat) · Revenue: $720M actual

  • Q1 2025

    EPS: $1.01 actual vs $0.95 estimate (beat) · Revenue: $665M actual

  • Q4 2024

    EPS: $1.42 actual vs $1.38 estimate (beat) · Revenue: $730M actual

RVTY Competitive Positioning

Revvity, Inc. (RVTY) is tracked alongside these names in Diagnostics & Research on DailyIQ.

  • A — Agilent Technologies, Inc.

  • ABBV — AbbVie Inc.

  • ABCL — AbCellera Biologics Inc.

  • ABT — Abbott Laboratories

  • ALGN — Align Technology, Inc.

What Moves RVTY Stock?

Revvity's stock performance is driven by its innovation in life sciences tools and diagnostic solutions, alongside its financial results and strategic market positioning.

Product Innovation

Revvity recently launched advanced platforms like the Opera Phenix OptIQ and EnVision Nexus One at SLAS2026, aimed at accelerating drug discovery workflows.

These cutting-edge technologies are designed to enhance research capabilities, potentially driving higher adoption rates and revenue growth, which can positively impact stock valuation.

Financial Performance

The company has demonstrated consistent earnings per share growth and an upward trend in revenue over the past four quarters.

Beating EPS estimates in all recent quarters suggests operational efficiency and strong market demand, providing a solid foundation for investor confidence and stock appreciation.

Market Dynamics

While Revvity benefits from strong demand in diagnostics and research, it faces challenges such as valuation concerns and weakness in the China diagnostics market.

Navigating these market-specific headwinds and capitalizing on global opportunities will be crucial for sustained stock performance and mitigating potential downside risks.

Key insight: Revvity's stock is primarily influenced by its ability to innovate and launch new technologies that drive revenue growth, alongside its consistent financial performance. Investors should monitor the adoption of its new platforms and its strategic response to market-specific challenges to gauge future stock trajectory.

Frequently Asked Questions About RVTY

Is Revvity, Inc. (RVTY) stock a good investment?

Revvity's investment appeal often centers on its role in health sciences, providing solutions for research and diagnostics. The company's focus on genetic testing and drug discovery workflows, supported by new technology launches, could drive future growth. Investors may consider the company's consistent EPS growth and revenue trends alongside competitive pressures and market dynamics.

What drives Revvity (RVTY) stock price?

The stock price of Revvity, Inc. is influenced by its performance in the diagnostics and research sectors, particularly the demand for its genetic testing and drug discovery solutions. New product introductions, such as those presented at SLAS2026, and the company's ability to capture market share in key areas like oncology and immunodiagnostics are significant factors. Broader healthcare spending trends and investor sentiment towards health science companies also play a role.

Does Revvity (RVTY) pay a dividend?

Revvity, Inc. currently does not pay a regular dividend to its shareholders. The company has historically focused on reinvesting its earnings back into the business to fund research, development, and strategic initiatives. Investors seeking income may need to consider other investment opportunities or evaluate Revvity's potential for future capital returns if its strategy evolves.

What are the risks of investing in Revvity (RVTY) stock?

Risks associated with Revvity stock include potential competitive pressures within the diagnostics and research markets, as well as macroeconomic factors affecting healthcare spending. Concerns regarding valuation and potential weakness in specific geographic markets, such as China diagnostics, have been noted. The company's reliance on innovation and the successful adoption of new technologies also presents an inherent risk.

How is Revvity's (RVTY) valuation assessed?

Valuation for Revvity, Inc. (RVTY) is often assessed by comparing its price-to-earnings (P/E) ratio to industry averages and its historical multiples. Analysts also consider revenue growth, earnings per share (EPS) trends, and the company's market capitalization relative to its peers. The perceived value of its technology platforms and its position in the growing health sciences market are key components of its valuation.

What is Revvity's (RVTY) investment thesis?

The bull case for Revvity centers on its established position in health sciences, providing critical tools for research, diagnostics, and drug discovery. Continued innovation, as evidenced by new product launches, and consistent EPS growth suggest a pathway for future expansion. The company's ability to capitalize on trends in personalized medicine and advanced genomic workflows could underpin its long-term growth trajectory.

How has Revvity (RVTY) performed recently?

Revvity, Inc. has demonstrated consistent EPS growth over the last four reported quarters, with revenue also trending upwards. The company has a track record of beating EPS estimates, indicating operational strength. Recent news highlights new platform launches aimed at accelerating drug discovery, suggesting a focus on innovation to drive future performance.

What are Revvity's (RVTY) growth catalysts?

Key growth catalysts for Revvity include the successful commercialization of its newly launched platforms, such as the Opera Phenix OptIQ and EnVision Nexus One systems, which aim to enhance drug discovery workflows. Expansion in emerging markets and the increasing demand for advanced genetic testing and diagnostics solutions are also significant drivers. Strategic acquisitions or partnerships could further accelerate its growth.

What is Revvity's (RVTY) competitive landscape?

Revvity operates in a competitive landscape within the health sciences sector, facing rivals in diagnostics, research instruments, and drug discovery services. While its broad suite of offerings provides a competitive advantage, companies like Eli Lilly and Johnson & Johnson, though in different primary industries, represent the broader competitive pressures within the healthcare ecosystem. Continuous innovation and effective market penetration are crucial for maintaining its competitive edge.

Learn More

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles